Bank Vontobel AG Share Price

Certificat

RBSAAV

CH1333287865

Real-time Bid/Ask 03:35:44 04/07/2024 pm IST
96.1 CHF / 96.4 CHF -0.36% Intraday chart for Bank Vontobel AG
Current month-0.10%
1 month-2.82%
Date Price Change
02/24/02 96.6 -0.41%
01/24/01 97 +0.31%
28/24/28 96.7 -0.82%
26/24/26 97.5 -0.61%

Delayed Quote Swiss Exchange

Last update July 02, 2024 at 08:50 pm IST

More quotes

Static data

Product typeObligations Convertibles
Buy / SellCALL
Underlying BASILEA PHARMACEUTICA AG
IssuerLogo Issuer Vontobel Vontobel
RBSAAV
ISINCH1333287865
Date issued 04/04/2024
Strike 50 CHF
Maturity 04/04/2025 (275 Days)
Parity 0.05 : 1
Emission price 100 CHF
Emission volume N/A
Settlement les deux
Currency CHF

Technical Indicators

Highest since issue 99.6 CHF
Lowest since issue 96.2 CHF
Spread 3 CHF
Spread %0.31%

Company Profile

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Sector
-
More about the company

Ratings for Basilea Pharmaceutica AG

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Basilea Pharmaceutica AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
38.55 CHF
Average target price
71.2 CHF
Spread / Average Target
+84.70%
Consensus
  1. Stock Market
  2. Certificates
  3. RBSAAV Certificat